Inflammation in Heart Failure

Murphy, Sean; Kakkar, Rahul; McCarthy, Cian P.; Januzzi, James L.

doi:10.1016/j.jacc.2020.01.014

Cited by 352 publications

(195 citation statements)

References 115 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…Therefore, +dp/dt max is a good indicator of the acute changes in contractile performance. The −dp/dt max reflects the maximum rate of myocardial fiber elongation during myocardial diastole [ 19 , 20 ]. Both are common indicators to evaluate myocardial contraction and diastolic performance.…”

Section: Discussionmentioning

confidence: 99%

Crude Radix Aconiti Lateralis Preparata (Fuzi) with Glycyrrhiza Reduces Inflammation and Ventricular Remodeling in Mice through the TLR4/NF-κB Pathway

Yan

Mao

Jin

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Radix Aconiti Lateralis Preparata (Fuzi) is a traditional Chinese medicine. Its alkaloids are both cardiotonic and cardiotoxic; however, the underlying mechanisms are unclear. Compatibility testing and processing are the primary approaches used to reduce the toxicity of aconite preparations. The purpose of this study was to compare the effects of crude Fuzi (CFZ), CFZ combined with Glycyrrhiza (Gancao) (CFZ+GC), and prepared materials of CFZ (PFZ) on heart failure (HF) in C57BL/6J mice and explore the potential mechanisms of action of CFZ. Transverse aortic constriction (TAC) was used to generate the HF state, and CFZ (1.5 g·mL−1), PFZ (1.5 g·mL−1), or CFZ+GC (1.8 g·mL−1) was orally administered to the HF-induced mice daily. For the subsequent 8 weeks, hemodynamic indicators, ventricular pressure indices, and mass indices were evaluated, and histopathological imaging was performed. CFZ, CFZ+GC, and PFZ significantly improved left ventricular function and structure and reduced myocardial damage. CFZ+GC was more effective than CFZ and PFZ, whereas CFZ had higher toxicity than CFZ+GC and PFZ. CFZ and CFZ+GC attenuated ischemia-induced inflammatory responses and also inhibited Toll-like receptor-4 (TLR4) and nuclear factor kappa beta (NF-κB) action in the heart. Moreover, mass spectrometry analysis revealed a decrease in the levels of toxic components of CFZ+GC, whereas those of the protective components were increased. This study suggested that GC reduces the toxicity and increases the efficacy of CFZ on HF induced by TAC. Furthermore, GC+CFZ reduces the risk of HF by ameliorating the inflammation response, which might be partially related to the inhibition of the TLR4/NF-κB pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Crude Radix Aconiti Lateralis Preparata (Fuzi) with Glycyrrhiza Reduces Inflammation and Ventricular Remodeling in Mice through the TLR4/NF-κB Pathway

Yan

Mao

Jin

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…In view of the important role of inflammation in HF, anti-inflammatory therapy has become desirable against HF. However, in clinical trials, most of the direct anti-inflammatory or anti-cytokine therapies have not demonstrated significant benefits for improving outcomes in patients with HF ( 71 , 72 ).…”

Section: Sglt2 Inhibitorsmentioning

confidence: 99%

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure

Zeng

Zhou

Liu

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure (HF) is a common complication or late-stage manifestation of various heart diseases. Numerous risk factors and underlying causes may contribute to the occurrence and progression of HF. The pathophysiological mechanisms of HF are very complicated. Despite accumulating advances in treatment for HF during recent decades, it remains an intractable clinical syndrome with poor outcomes, significantly reducing the quality of life and expectancy of patients, and imposing a heavy economic burden on society and families. Although initially classified as antidiabetic agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated reduced the prevalence of hospitalization for HF, cardiovascular death, and all-cause death in several large-scale randomized controlled clinical trials. These beneficial effects of SGLT-2 inhibitors can be attributed to multiple hemodynamic, inflammatory and metabolic mechanisms, not only reducing the serum glucose level. SGLT2 inhibitors have been used increasingly in treatment for patients with HF with reduced ejection fraction due to their surprising performance in improving the prognosis. In addition, their roles and mechanisms in patients with HF with preserved ejection fraction or acute HF have also attracted attention. In this review article, we discuss the possible mechanisms and applications of SGLT2 inhibitors in HF.

show abstract

“…Регуляция фибротической активности активированных фибробластов также осуществляется через ионные каналы с транзиторным рецепторным потенциалом (ген TRPC) путем транспорта внутрь данных клеток ионов кальция [26]. Секретируемые активированными фибробластами медиаторы воспалениятакие как моноцитарный хемоаттрактантный белок (ген CCL2), фактор некроза опухоли-α (ген TNF), интерлейкин-1β (ген IL1B) и интерлейкин-6 (ген IL6), также ауто-и паракринно стимулируют их пролиферацию и синтез белков ЭЦМ [27][28][29].…”

Section: патологическая анатомия и физиология фиброза миокардаunclassified

Biomarkers of myocardial fibrosis and their genetic regulation in patients with heart failure

Печерина

Kutikhin

2020

Russ J Cardiol

View full text Add to dashboard Cite

Currently, the development of chronic heart failure (CHF) is considered from the perspective of pathological structural remodeling of myocardium and fibrosis. Despite the widespread use of molecular genetic markers in clinical practice, only a small number of them are used to evaluate remodeling processes, as well as to predict potential complications associated with heart failure (HF). In addition, the relationship between many biomarkers with instrumental and histological confirmation of myocardial fibrosis has not yet been determined. Myocardial fibrosis remains quite debatable and controversial subject, which actualizes the further study of this direction. The discovery of pathogenetic and diagnostic markers of myocardial fibrosis could contribute to the development of targeted therapy. Of particular interest is the search for possible pathogenetic markers, since this is relevant for clinical practice.

show abstract

Inflammation in Heart Failure

Cited by 352 publications

References 115 publications

Crude Radix Aconiti Lateralis Preparata (Fuzi) with Glycyrrhiza Reduces Inflammation and Ventricular Remodeling in Mice through the TLR4/NF-κB Pathway

Crude Radix Aconiti Lateralis Preparata (Fuzi) with Glycyrrhiza Reduces Inflammation and Ventricular Remodeling in Mice through the TLR4/NF-κB Pathway

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure

Biomarkers of myocardial fibrosis and their genetic regulation in patients with heart failure

Contact Info

Product

Resources

About